Cited 4 times in
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2022-09-14T01:47:14Z | - |
dc.date.available | 2022-09-14T01:47:14Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 1078-0432 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/190609 | - |
dc.description.abstract | Purpose: In MONARCH 2, abemaciclib plus fulvestrant significantly prolonged progression-free survival (PFS) and overall survival (OS) versus placebo plus fulvestrant in patients with hormone receptor positive (HR+), HER2- advanced breast cancer. This exploratory analysis assessed the efficacy of abemaciclib plus fulvestrant across subgroups of patients receiving study therapy as first- or second-line treatment for metastatic disease. Patients and methods: Improvements were estimated using Cox models, and a test of interactions of subgroups with treatment was performed. Results: The benefit in PFS [first-line, HR, 0.57; 95% confidence interval (CI), 0.45-0.73; second-line, HR, 0.48; 95% CI, 0.36-0.64] and OS (first-line, HR, 0.85; 95% CI, 0.64-1.14; second-line, HR, 0.66; 95% CI, 0.46-0.94) was observed across both subgroups, consistent with the intent-to-treat (ITT) population. In first-line patients (abemaciclib arm, n = 265; placebo arm, n = 133), the numerically largest effect on PFS and OS was observed in patients with primary resistance to endocrine therapy (ET; PFS, HR, 0.40; 95% CI, 0.26-0.63; OS, HR, 0.58; 95% CI, 0.35-0.97) and visceral disease (PFS, HR, 0.54; 95% CI, 0.39-0.73; OS, HR, 0.82; 95% CI, 0.58-1.20). In second-line patients (abemaciclib arm, n = 170; placebo arm, n = 86), a numerical benefit in PFS and OS was observed across primary and secondary ET resistance, with numerically more pronounced effects observed in patients with visceral disease (PFS, HR, 0.39; 95% CI, 0.27-0.57; OS, HR, 0.51; 95% CI, 0.33-0.81). Prolongation of time to second disease progression, time to chemotherapy, and chemotherapy-free survival was observed in both subgroups. Conclusions: Consistent with the ITT population, a benefit in PFS and OS was observed across the first- and second-line subgroups in MONARCH 2. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Association for Cancer Research | - |
dc.relation.isPartOf | CLINICAL CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aminopyridines / administration & dosage* | - |
dc.subject.MESH | Antineoplastic Agents, Hormonal / administration & dosage* | - |
dc.subject.MESH | Benzimidazoles / administration & dosage* | - |
dc.subject.MESH | Breast Neoplasms / chemistry | - |
dc.subject.MESH | Breast Neoplasms / drug therapy* | - |
dc.subject.MESH | Breast Neoplasms / pathology | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fulvestrant / administration & dosage* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Receptor, ErbB-2 / analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Patrick Neven | - |
dc.contributor.googleauthor | Stephen R D Johnston | - |
dc.contributor.googleauthor | Masakazu Toi | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.contributor.googleauthor | Kenichi Inoue | - |
dc.contributor.googleauthor | Xavier Pivot | - |
dc.contributor.googleauthor | Olga Burdaeva | - |
dc.contributor.googleauthor | Meena Okera | - |
dc.contributor.googleauthor | Norikazu Masuda | - |
dc.contributor.googleauthor | Peter A Kaufman | - |
dc.contributor.googleauthor | Han Koh | - |
dc.contributor.googleauthor | Eva-Maria Grischke | - |
dc.contributor.googleauthor | PierFranco Conte | - |
dc.contributor.googleauthor | Yi Lu | - |
dc.contributor.googleauthor | Nadine Haddad | - |
dc.contributor.googleauthor | Karla C Hurt | - |
dc.contributor.googleauthor | Antonio Llombart-Cussac | - |
dc.contributor.googleauthor | George W Sledge | - |
dc.identifier.doi | 10.1158/1078-0432.CCR-20-4685 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J00564 | - |
dc.identifier.pmid | 34376533 | - |
dc.identifier.url | https://aacrjournals.org/clincancerres/article/27/21/5801/671728/MONARCH-2-Subgroup-Analysis-of-Patients-Receiving | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.citation.volume | 27 | - |
dc.citation.number | 21 | - |
dc.citation.startPage | 5801 | - |
dc.citation.endPage | 5809 | - |
dc.identifier.bibliographicCitation | CLINICAL CANCER RESEARCH, Vol.27(21) : 5801-5809, 2021-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.